We advocate for people suffering learning disabilities from prenatal anti-epileptic drug exposure. Our goal is to inform all women across the country that AEDs can be harmful to a baby before birth.

Pregnant women are not allowed to take any medications. But what if you were required to take one of these medications to prevent an epileptic seizure? In every 1,000 births four to five are born to women with epilepsy. In the last fifty years, roughly 1,000,000 babies have been exposed to different anti-seizure drugs that can cause a learning disability and, depending on the type of medication, a lower IQ. These drugs are also used to control migraines and are prescribed for some psychological disorders. According to the Neurodevelopmental Effects of Antiepileptic Drugs study that began in 1999, there are several of these drugs that do alter a baby’s brain. Some of the drugs cause lower IQ, learning disabilities, and possibly communication difficulties.

Once the NEAD study published its findings in 2007-08, our founder began looking for a support group, but was unable to find one. She realized that her background uniquely qualified her to start a support group and make plans for future projects to help these children born to moms who had to take anti-seizure drugs.

According to the National Institute of Health, per patient funding for the Research and Disease Categories as listed below show the problem we have gaining support for non-medical studies. We hope to change this oversight and develop teaching/training methods to help those affected before birth by anti-seizure medications.

There are no specialized services, information, or support for this group provided by government agencies other than what already exists in the education system for learning disabilities. While it is important to develop learning strategies for these children and adults. The organization’s first project to is to spread the word to all women about anti-seizure drugs and their effects on a baby’s brain before birth. We hope to connect with women who have used these drugs during pregnancy as the Woman 2 Woman Campaign progresses.


Simone Graham

Health Information Services Executive Directior